Evidence map›Paper›PMID 42016758›Full record

ArticleExploration (Beijing, China)2026

When Rare Is Not Small: Amyotrophic Lateral Sclerosis Initiatives and Therapy.

Yang Liu, Xue Xia, Yingfang Chen, Haoying Yang, Xiaochen Chen, Lei Cai, Bingyang Shi

Abstract read
In one paragraph

Article in Exploration (Beijing, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yang LiuThe Zhongzhou Laboratory for Integrative Biology, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences Henan University Kaifeng Henan China.ORCID https://orcid.org/0000-0002-8752-4346
Xue XiaThe Zhongzhou Laboratory for Integrative Biology, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences Henan University Kaifeng Henan China.ORCID https://orcid.org/0000-0001-8334-2177
Yingfang ChenBeijing AskHelpU Medical Tech Co. Ltd. Beijing China.
Haoying YangThe Zhongzhou Laboratory for Integrative Biology, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences Henan University Kaifeng Henan China.
Xiaochen ChenThe Zhongzhou Laboratory for Integrative Biology, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences Henan University Kaifeng Henan China.
Lei CaiBeijing AskHelpU Medical Tech Co. Ltd. Beijing China.
Bingyang ShiThe Zhongzhou Laboratory for Integrative Biology, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences Henan University Kaifeng Henan China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the precision-medicine era, rare diseases must not be sidelined in translational infrastructure. The Mr. Cai Lei-led "Ice-Breaking Team" turns an amyotrophic lateral sclerosis patient community into a sustainable ecosystem, realigning philanthropy, data, and research and development to reshape rare-disease pipelines and guide precision therapies, offering a replicable blueprint for rare-disease strategies.

Identifiers

PMID42016758
PMCPMC13094513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.